Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of LupusErythematosus

Housman, Tamara Salam; Jorizzo, Joseph L.; McCarty, Martha Ann; Grummer, Sarah E.; Fleischer, Alan B.; Sutej, Paul G.

doi:10.1001/archderm.139.1.50

Cited by 75 publications

(45 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thalidomide, including low-dose regimens, is effective in recalcitrant disease, but a high risk-benefit profile makes its use relatively prohibitive. [81][82][83][84] Other agents used include dapsone, 74 94 ) interferon-alfa-2, and monoclonal anti-CD4 antibodies. 95 A few case reports suggest that topical tacrolimus, [96][97][98] imiquimod, 99 and tazarotene 100 may prove to be effective therapeutic alternatives.…”

Section: Discoid Lupus Erythematosusmentioning

confidence: 99%

Update on primary cicatricial alopecias

Ross

Tan

Shapiro

2005

Journal of the American Academy of Dermatology

256

323

View full text Add to dashboard Cite

Section: Discoid Lupus Erythematosusmentioning

confidence: 99%

Update on primary cicatricial alopecias

Ross

Tan

Shapiro

2005

Journal of the American Academy of Dermatology

256

323

View full text Add to dashboard Cite

“…Treatment with single-agent or combination with aminoquinoline antimalarial will suffice for 75% of SCLE patients. In particular clinical cases, the remaining 25%, have been treated with other pharmacologic forms, as antiinflammatory or systemic immunosuppressive-immunomodulatory therapies, which includes auranofin, dapsone, thalidomide, retinoids, interferon, and immunosuppressive agents [53][54][55][56]. …”

Section: Subacute Cutaneous Lupus Erythematosusmentioning

confidence: 99%

Cutaneous manifestations of systemic lupus erythematosus

2018

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease of unknown etiology with many clinical manifestations. The skin is one of the target organs most variably affected by the disease. The American College of Rheumatology (ACR) established 11 criteria as a classificatory instrument to operationalise the definition of SLE in clinical trials. They were not intended to be used to diagnose individuals and do not do well in that capacity. Cutaneous lesions account for four of these 11 revised criteria of SLE. Skin lesions in patients with lupus may be specific or nonspecific. This paper covers the SLE-specific cutaneous changes: malar rash, discoid rash, photosensitivity, and oral mucosal lesions as well as SLE nonspecific skin manifestations, their pathophysiology, and management. A deeper thorough understanding of the cutaneous manifestations of SLE is essential for diagnosis, prognosis, and efficient management. Thus, dermatologists should cooperate with other specialties to provide optimal care of SLE patient.

show abstract

“…Thalidomide, [94,95] topical immunomodulators (0.1% tacrolimus [96][97][98] and 1% pimecrolimus [99,100] ), oral vitamin E, [101] oral gold, [102] dapsone, [103] mycophenolate mofetil, [104] methotrexate, [105,106] azathioprine, [60] clofazamine, [60] systemic or intralesional INFα2, [107,108] monoclonal anti-CD4 antibodies, [109] topical 5-FU, [110] topical tazarotene, [111] imiquimod. [112] LPP…”

Section: Third Linementioning

confidence: 99%

What′s new in cicatricial alopecia?

Dogra¹,

Sarangal²

2013

Indian J Dermatol Venereol Leprol

View full text Add to dashboard Cite

Scalp hairs complete the body self-image and patients with alopecia suffer from overt disfiguration, leading to psychosocial embarrassment and significant lack of self-esteem. Hence an early diagnosis and an aggressive treatment in the case of active hair loss are crucial in the management of scarring alopecia. This review presents a comprehensive study of newer theories in aetiopathogenesis, evolving diagnostic modalities and a step ladder approach in management of primary cicatricial alopecia.

show abstract

Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of LupusErythematosus

Cited by 75 publications

References 21 publications

Update on primary cicatricial alopecias

Update on primary cicatricial alopecias

Cutaneous manifestations of systemic lupus erythematosus

What′s new in cicatricial alopecia?

Contact Info

Product

Resources

About